Michael Mahoney Net Worth

The estimated Net Worth of Michael F Mahoney is at least $197 million dollars as of 5 September 2024. Mr. Mahoney owns over 162,777 units of Boston Scientific stock worth over $134,610,542 and over the last 13 years he sold BSX stock worth over $46,748,968. In addition, he makes $15,764,100 as Chairman of the Board, President et Chief Executive Officer at Boston Scientific.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Mahoney BSX stock SEC Form 4 insiders trading

Michael has made over 79 trades of the Boston Scientific stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 162,777 units of BSX stock worth $13,212,609 on 5 September 2024.

The largest trade he's ever made was exercising 372,611 units of Boston Scientific stock on 1 January 2015 worth over $30,904,356. On average, Michael trades about 71,082 units every 40 days since 2011. As of 5 September 2024 he still owns at least 1,622,987 units of Boston Scientific stock.

You can see the complete history of Mr. Mahoney stock trades at the bottom of the page.

Michael Mahoney biography

Michael F. Mahoney serves as Chairman of the Board, President, Chief Executive Officer of the Company. He joined the Company as our President in October 2011, and became our President and Chief Executive Officer and a director in November 2012. Mr. Mahoney became our Chairman of the Board in May 2016. Prior to joining the Company, he was Worldwide Chairman of the Medical Devices and Diagnostics division of Johnson & Johnson from January 2011 to September 2011, overseeing 50,000 employees and seven franchises. Prior to assuming this position, Mr. Mahoney served as Worldwide Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, Mr. Mahoney served as President and Chief Executive Officer of Global Healthcare Exchange, a provider of supply chain solutions and services that brings together hospitals, manufacturers, distributors and group purchasing organizations. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business.

What is the salary of Michael Mahoney?

As the Chairman of the Board, President et Chief Executive Officer of Boston Scientific, the total compensation of Michael Mahoney at Boston Scientific is $15,764,100. There are no executives at Boston Scientific getting paid more.

How old is Michael Mahoney?

Michael Mahoney is 55, he's been the Chairman of the Board, President et Chief Executive Officer of Boston Scientific since 2016. There are 16 older and 10 younger executives at Boston Scientific. The oldest executive at Boston Scientific Corp. is Yoshiaki Fujimori, 69, who is the Independent Director.

What's Michael Mahoney's mailing address?

Michael's mailing address filed with the SEC is 300 BOSTON SCIENTIFIC WAY, , MARLBOROUGH, MA, 01752-1234.

Insiders trading at Boston Scientific

Over the last 20 years, insiders at Boston Scientific have traded over $938,841,783 worth of Boston Scientific stock and bought 1,398,972 units worth $16,231,539 . The most active insiders traders include Peter M Nicholas, John E Abele et Michael F Mahoney. On average, Boston Scientific executives and independent directors trade stock every 3 days with the average trade being worth of $4,899,929. The most recent stock trade was executed by Michael F Mahoney on 5 September 2024, trading 162,777 units of BSX stock currently worth $13,212,609.

What does Boston Scientific do?

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.

Complete history of Mr. Mahoney stock trades at Baxter International, Boston Scientific et CVS Health Corp

Boston Scientific executives and stock owners

Boston Scientific executives and other stock owners filed with the SEC include:

• Michael Mahoney,
  Chairman of the Board, President, Chief Executive Officer
• Daniel Brennan,
  Chief Financial Officer, Executive Vice President
• Joseph Fitzgerald,
  Executive Vice President, President, Interventional Cardiology
• Edward Mackey,
  Executive Vice President - Operations
• David Pierce,
  Executive Vice President and President, MedSurg and President, Endoscopy
• Michael F. Mahoney,
  Chairman, Pres & CEO
• Daniel J. Brennan,
  Exec. VP & CFO
• Joseph M. Fitzgerald,
  Exec. VP & Pres of Interventional Cardiology
• Edward F. Mackey,
  Exec. VP of Global Operations
• Jeffrey B. Mirviss,
  Exec. VP & Pres of Peripheral Interventions
• Edward Ludwig,
  Lead Independent Director
• Charles Dockendorff,
  Independent Director
• David Roux,
  Independent Director
• John Sununu,
  Independent Director
• Donna James,
  Independent Director
• Nelda Connors,
  Independent Director
• Ellen Zane,
  Independent Director
• Stephen MacMillan,
  Independent Director
• Yoshiaki Fujimori,
  Independent Director
• John Sorenson,
  Senior Vice President - Manufacturing and Supply Chain
• Meghan Scanlon,
  Senior Vice President and President, Urology and Pelvic Health
• Scott Olson,
  Senior Vice President and President, Rhythm Management
• Maulik Nanavaty,
  Senior Vice President and President - Neuromodulation
• Wendy Carruthers,
  Senior Vice President - Human Resources
• Desiree Ralls-Morrison,
  Senior Vice President, General Counsel, Corporate Secretary
• Jodi Eddy,
  Senior Vice President, Chief Information Officer
• Eric Thepaut,
  Executive Vice President and President - Europe, Middle East and Africa
• Jeffrey Mirviss,
  Executive Vice President and President - Peripheral Interventions
• Ian Meredith,
  Executive Vice President, Global Chief Medical Officer
• Arthur Butcher,
  Executive Vice President and President, Asia Pacific
• Catherine Jennings,
  VP of Global Marketing & New Bus. Devel. of Peripheral Interventions
• Vance R. Brown,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Susan Vissers Lisa,
  VP of Investor Relations
• Jodi Euerle Eddy,
  Sr. VP and Chief Information & Digital Officer
• Jonathan R Monson,
  VP, Global Controller & Chief Accounting Officer
• Vance R Brown,
  SVP, GC and Corp. Secretary
• Timothy A. Pratt,
  EVP & General Counsel
• Supratim Bose,
  EVP & President, Asia-Pacific
• Michael P. Phalen,
  SVP & President, Endoscopy
• Keith D Dawkins,
  Sr. VP, Chief Medical Officer
• Kevin J. Ballinger,
  EVP & Pres, Interven Cardio
• Cheryl Pegus,
  Director
• David S Wichmann,
  Director
• Xin Warren Wang,
  SVP and Pres, Asia Pacific
• Peter M Nicholas,
  Director
• Kristina M Johnson,
  Director
• Nicholas J Jr Nicholas,
  Director
• Karen Prange,
  SVP&Pres, Uro & Women's Health
• Ernest Mario,
  Director
• John E Abele,
  Director
• Uwe E Reinhardt,
  Director
• Katharine T Bartlett,
  Director
• Jean Fitterer Lance,
  SVP & Chief Compliance Officer
• Kenneth Pucel,
  EVP, Operations
• Bruce L Byrnes,
  Director
• John Michael Onuscheck,
  SVP & Pres-Neuromodulation
• Jeffrey D Capello,
  Chief Accounting Officer
• Otha T. Iii Spriggs,
  SVP, Human Resources
• William Kucheman,
  SVP & Group President
• John Raymond Elliott,
  Director
• Lawrence R Neumann,
  SVP and Pres, Emerging Markets
• John B. Pedersen,
  Pres,Uro & Women's Health
• Brian R Burns,
  SVP - Quality
• Ray J Groves,
  Director
• Sam R Leno,
  CFO & EVP Finance & IS
• Stephen F Moreci,
  Sr. VP, Endosurgery
• Marye Anne Fox,
  Director
• Fred Colen,
  EVP
• John E Pepper,
  Director
• James Gilbert,
  EVP
• Donovan Paul,
  SVP, Corporate Comm
• David W Mc Faul,
  Senior VP International
• Ursula M Burns,
  Director
• Warren B Rudman,
  Director
• William F Jr Mcconnell,
  SVP, Administration CRM
• Donald S Baim,
  EVP, Chief Med. & Sci. Officer
• Lucia Luce Quinn,
  Exec. Vice President-HR
• James R Tobin,
  President & CEO
• Paul W Sandman,
  EVP and General Counsel
• Paul A Laviolette,
  COO
• Nancy Ann Deparle,
  Director
• Joel Lawrence Fleishman,
  Director
• David C Habiger,
  Director
• Jonathan Monson,
  SVP, Global Controller and CAO
• Emily Woodworth,
  SVP, Global Controller and CAO
• Jessica L Mega,
  Director
• Susan E Morano,
  Director